Advanced Melanoma With Resistance to PD-1 Inhibition May Derive Benefit From BO-112 Plus Pembrolizumab

Source: Cancer Network, April 2022

Novel BO-112 when combined with pembrolizumab may offer a new treatment option for patients with advanced melanoma and PD-1 inhibitor therapy resistance.

Advanced melanoma with anti–PD-1 therapy resistance that was treated with BO-112 plus pembrolizumab (Keytruda) demonstrated that the combination could be an efficacious option in this patient group, according to data presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting from the phase 2 SPOTLIGHT203 trial (NCT04570332).

At a median follow-up of 4.1 months (95% CI, 3.9-6.3), findings showed that among patients evaluable for response (n = 40), the combination of BO-112 and pembrolizumab achieved an overall response rate (ORR) of 25%, including a complete response rate of 10% and a partial response rate of 15%. Additionally, 40% had stable disease, and the disease control rate (DCR) was 65%.